The Life Sciences Report - This Is What The Experts Are Saying About CPRX. ((( POST )))
The Life Sciences Report 10/13/14
Catalyst Pharmaceutical Partners Inc.
Echo He, Maxim Group (9/24/13) "We are initiating coverage of Catalyst Pharmaceutical Partners Inc. with a Buy rating and a price target of $4. . .we believe Firdapse has a high probability of success. . .iIn addition, the company has a preclinical-stage drug (CPP-115) with initial indications as infantile spasms and Tourette's disorder. We see upside to the stock at current levels, given high possibility of positive pivotal results and pipeline opportunities."
Raghuram Selvaraju, Aegis Capital Corp. (9/6/13) "In the wake of the new equity offering, which should leave Catalyst Pharmaceutical Partners Inc. with $20M in pro forma cash and sufficient capital to sustain operations through 2014 and the filing of a new drug application for Firdapse, we maintain our Buy rating and raise target from $3.50 to $4/share. This reflects the lower dilution associated with Catalyst's ability to successfully raise capital at a higher price per share than was previously anticipated."
Andrew Fein, H.C. Wainwright & Co. (8/29/13) "We are initiating coverage on Catalyst Pharmaceutical Partners Inc. with a Buy rating and price target of $5. . .the company inherited Biomarin's ongoing pivotal phase 3 study of Firdapse in Lambert-Eaton Myasthenic Syndrome (LEMS). . .Catalyst expects topline phase 3 results in H1/14, an NDA filing in 2015 and U.S. commercial kickoff in 2016, although the recent receipt of breakthrough therapy designation for Firdapse in LEMS may accelerate this projected timeline considerably. . . As an externally vetted and commercially derisked orphan asset, Firdapse is the company's primary value driver."